

**Table S2.** Univariate and multivariate analyses of *Mash1* and *LMO3* mRNA expression as well as other prognostic factors in primary neuroblastomas

Factor	n	p-value	H.R.	C.I.
Age ( $\geq 1$ year vs. $< 1$ year)	59 vs. 41	0.011	3.2	(1.3, 9.5)
Stage (1, 2, 4s vs. 3, 4)	44 vs. 56	$< 0.001$	7.3	(2.5, 30.9)
<i>MYCN</i> (amplified vs. single)	17 vs. 83	$< 0.001$	9.7	(4.3, 21.9)
Origin (non-adrenal vs. adrenal)	47 vs. 53	0.002	3.9	(1.6, 10.6)
<i>Mash1</i> expression (high vs. low)	30 vs. 70	0.048	2.2	(1.0, 4.8)
<i>LMO3</i> expression (high vs. low)	26 vs. 74	0.012	2.9	(1.3, 6.6)
Age ( $\geq 1$ year vs. $< 1$ year)	59 vs. 41	0.006	3.5	(1.4, 10.5)
<i>Mash1</i> expression (high vs. low)	30 vs. 70	0.024	2.5	(1.1, 5.5)
Stage (1, 2, 4s vs. 3, 4)	44 vs. 56	$< 0.001$	6.7	(2.2, 29.1)
<i>Mash1</i> expression (high vs. low)	30 vs. 70	0.559	1.3	(0.6, 2.8)
<i>MYCN</i> (amplified vs. single)	17 vs. 83	$< 0.001$	9.7	(4.2, 22.3)
<i>Mash1</i> expression (high vs. low)	30 vs. 70	0.093	2.0	(0.9, 4.4)
Origin (non-adrenal vs. adrenal)	47 vs. 53	0.002	3.8	(1.6, 10.3)
<i>Mash1</i> expression (high vs. low)	30 vs. 70	0.064	2.1	(1.0, 4.6)
Age ( $\geq 1$ year vs. $< 1$ year)	59 vs. 41	0.014	3.0	(1.2, 9.1)
<i>LMO3</i> expression (high vs. low)	26 vs. 74	0.015	2.9	(1.2, 6.5)
Stage (1, 2, 4s vs. 3, 4)	44 vs. 56	$< 0.001$	7.0	(2.4, 29.7)
<i>LMO3</i> expression (high vs. low)	26 vs. 74	0.021	2.7	(1.2, 6.3)
<i>MYCN</i> (amplified vs. single)	17 vs. 83	$< 0.001$	8.4	(3.6, 19.5)
<i>LMO3</i> expression (high vs. low)	26 vs. 74	0.213	1.7	(0.7, 4.1)
Origin (non-adrenal vs. adrenal)	47 vs. 53	0.003	3.6	(1.5, 9.9)
<i>LMO3</i> expression (high vs. low)	26 vs. 74	0.021	2.6	(1.2, 5.8)
<i>Mash1</i> expression (high vs. low)	30 vs. 70	0.022	2.6	(1.1, 5.7)
<i>LMO3</i> expression (high vs. low)	26 vs. 74	0.006	3.4	(1.4, 7.8)

Footnotes; n: number of samples, H.R.: hazard ratio, C.I.: confidence interval.